Managing IP is part of the Delinian Group, Delinian Limited, 8 Bouverie Street, London, EC4Y 8AX, Registered in England & Wales, Company number 00954730
Copyright © Delinian Limited and its affiliated companies 2023

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement
Cookies Settings

Vigilance key for drug innovators under China linkage regime

Karry Lai
December 01, 2020
Share
pharma1.jpg

A short litigation window and no notification system for drug patent owners remain pain points, despite progress

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Take a Free Trial or Login

Tags

ChinaIP StrategyNewsPatentsAsia-PacificJurisdictionsJurisdictions
lai-karry-300px.png
Karry Lai
Asia Reporter Managing IP
Contact
Karry joined the Managing IP team as Asia Reporter in October 2017. She covers all aspects of IP across Asia. Based in Hong Kong, she is also the Asia Reporter for International Financial Law Review. She has been with Euromoney’s Legal Media Group since December 2015.
more from across site and ros bottom lb

More from across our site

hand over a generic manual
Design patent lawyers want more from USPTO guidance
Lawyers wish the latest manual had more details on Federal Circuit cases and that training materials for design patent examiners were online
Rani Mehta, March 28, 2023
ITCTrendsCOVER.jpg
Three ITC trends shaping IP investigations
Counsel are eying domestic industry, concurrent PTAB proceedings and heightened scrutiny of cases before institution
Rani Mehta, March 24, 2023
JackDaniel's2023COVER.jpg
Jack Daniel’s SCOTUS hearing leaves counsel swaying
Jack Daniel’s has a good chance of winning its dispute over dog toys, but SCOTUS will still want to protect free speech, predict sources
Rani Mehta, March 24, 2023
AI img-min.jpeg
US Copyright Office’s AI guidance receives mixed reviews
AI users and lawyers discuss why the rulebook for registering AI-generated content may create problems and needs further work
Sukanya Sarkar, March 24, 2023
EPO
This week on MIP: EPO publishes G2/21, UK High Court backs Gilead
We provide a rundown of Managing IP’s news and analysis coverage from the week, and review what’s been happening elsewhere in IP
Rory O’Neill, March 24, 2023
EPO
EPO appeals board places conditions on post-application evidence
A technical effect must still be evident in the original patent filing, the EBoA said in its G2/21 decision today, March 23
Rory O’Neill, March 23, 2023
Different fresh chocolate ready for sale
What’s in a name? Why the lookalike argument needs to change
Brands should not be deterred from pursuing lookalike producers, and an unfair advantage claim could be the key, say Emma Teichmann and Geoff Steward at Stobbs
Geoff Steward, March 23, 2023
Rolls 2k-comp.jpg
InterDigital v Lenovo ruling prompts SEP owner rethink
Justice Mellor’s highly anticipated ruling surprised SEP owners and reassured implementers that the UK may not be so hostile after all
Rory O’Neill, March 23, 2023
Feb 19, 2020 Foster City / CA / USA - Gilead sign at their headq
High Court backs Gilead but issues case timeline warning
The England and Wales High Court's judgment comes ahead of a separate hearing concerning one of the patents-in-suit at the EPO
Rory O’Neill, March 23, 2023
India luggage.jpeg
What India’s legal market opening means for foreign IP firms
While the rules allow foreign firms to open local offices and offer IP services, a ban on litigation and practising Indian law could mean little will change
Sukanya Sarkar, March 23, 2023